Decision to list patient warming and cooling medical devices supplied by Bard Australia PTY. Limited
We are pleased to announce the approval of a listing agreement with Bard Australia PTY. Limited for the supply of patient warming and cooling products to DHBs.
What we are doing
We are pleased to announce the approval of a listing agreement with Bard Australia PTY. Limited (“Bard”) for the supply of patient warming and cooling products to DHBs.
In summary this will result in:
- Bard’s patient warming and cooling products being listed in Part III of Section H of the Pharmaceutical Schedule from 1 June 2019 under a national agreement that all DHBs may purchase under (“Agreement”); and
- DHBs being able to continue to purchase other suppliers’ brands of patient warming and cooling products as the agreement is not for sole supply.
Any changes to the original proposal?
No changes were made to the original proposal as a result of consultation feedback.
Who we think will be most interested
- Suppliers and Wholesalers
- DHB clinical and technical staff, including but not limited to:
- Anaesthetists and Anaesthetic Technicians
- Clinical engineers
- ICU Clinicians
- Procurement and supply chain personnel
Detail about this decision
The RFP was for non-exclusive national agreements for listing in the Pharmaceutical Schedule.
After completing the RFP evaluation process and consulting on the provisional Agreement reached with Bard, PHARMAC has decided to list the patient warming and cooling products in Part III of Section H of the Pharmaceutical Schedule from 1 June 2019.
DHBs can continue to choose which patient warming and cooling products they purchase, including those from other suppliers. DHBs that purchase patient warming and cooling products from Bard must do so under the terms and conditions, including pricing, in the Agreement, from 1 June 2019.
The Agreement includes terms and conditions for training and education to be provided by Bard on the appropriate use and maintenance of its product, which is to be provided at times as agreed with individual DHBs.
Our response to what you told us
We appreciate the time people took to review this consultation.
A summary of the main themes raised in feedback and our responses to the feedback received are set out below:
No technical or resource impacts anticipated for Ministry of Health.
If you have any questions about this decision, you can email us at email@example.com; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.